Positive Phase II data in wet AMD showing potential for dosing out to six months could spur partnering interest ahead of Phase III development.

The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.

Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.

Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.